Hydromorphone Hydrochloride (Monograph)
Brand name: Dilaudid
Drug class: Opoid Agonists
Warning
Risk Evaluation and Mitigation Strategy (REMS):
FDA approved a REMS for hydromorphone to ensure that the benefits outweigh the risks. The REMS may apply to one or more preparations of hydromorphone and consists of the following: medication guide and elements to assure safe use. See https://www.accessdata.fda.gov/scripts/cder/rems/.
- FDA drug safety communication (4/13/2023)500
-
As part of its ongoing efforts to address the nation’s opioid crisis, FDA is requiring several updates to the prescribing information of opioid pain medicines. The changes are being made to provide additional guidance for safe use of these drugs while also recognizing the important benefits when used appropriately. The changes apply to both immediate-release (IR) and extended-release/long-acting preparations (ER/LA).
-
Updates to the IR opioids state that these drugs should not be used for an extended period unless the pain remains severe enough to require an opioid pain medicine and alternative treatment options are insufficient, and that many acute pain conditions treated in the outpatient setting require no more than a few days of an opioid pain medicine.
-
Updates to the ER/LA opioids recommend that these drugs be reserved for severe and persistent pain requiring an extended period of treatment with a daily opioid pain medicine and for which alternative treatment options are inadequate.
-
A new warning is being added about opioid-induced hyperalgesia (OIH) for both IR and ER/LA opioid pain medicines. This includes information describing the symptoms that differentiate OIH from opioid tolerance and withdrawal.
-
Information in the boxed warning for all IR and ER/LA opioid pain medicines will be updated and reordered to elevate the importance of warnings concerning life-threatening respiratory depression, and risks associated with using opioid pain medicines in conjunction with benzodiazepines or other medicines that depress the central nervous system (CNS).
-
Other changes will also be required in various other sections of the prescribing information to educate clinicians, patients, and caregivers about the risks of these drugs.
Warning
- Overdose Risk with Improper Administration of Extended-release Tablets or 10-mg/mL Injection
-
Use highly concentrated injection (10 mg/mL) only in patients who are tolerant to opiate agonists; overdosage and/or death may result if confused with less concentrated formulations and used in patients who are not opiate tolerant.239 a (See Highly Concentrated [10-mg/mL] Injection under Dosage and Administration.)
-
Patients must swallow extended-release tablets whole to avoid exposure to a potentially fatal dose.246 Chewing, crushing, or dissolving the extended-release tablets can result in rapid release of hydromorphone and absorption of a potentially fatal dose.246
- Addiction, Abuse, and Misuse
-
Risk of addiction, abuse, and misuse, which can lead to overdosage and death.238 239 246 Assess each patient’s risk for addiction, abuse, and misuse before prescribing the drug; monitor all patients regularly for development of these behaviors or conditions.238 239 246 (See Addiction, Abuse, and Misuse under Cautions.)
- REMS
-
Clinicians are strongly encouraged to complete a REMS-compliant education program; appropriately counsel patients and/or caregivers with every prescription and emphasize importance of reading the medication guide; and consider other tools to improve patient, household, and community safety.238 246
- Respiratory Depression
-
Serious, life-threatening, or fatal respiratory depression may occur.238 239 246 Monitor for respiratory depression, especially during initiation of therapy and following dosage increases.238 239 246 (See Respiratory Depression under Cautions.)
- Accidental Exposure
-
Accidental ingestion of even 1 dose can result in fatal overdosage, particularly in children.238 246
- Neonatal Opiate Withdrawal
-
Prolonged maternal use of opiates during pregnancy can result in neonatal withdrawal syndrome, which may be life-threatening if not recognized and treated.238 239 246 Advise women who require such therapy during pregnancy of this risk and ensure appropriate treatment will be available.238 239 246 (See Pregnancy under Cautions.)
- Concomitant Use with Benzodiazepines or Other CNS Depressants
-
Concomitant use of opiate agonists with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death.238 239 246 416 417 418 700 701 702 703
-
Reserve concomitant use of opiate analgesics and benzodiazepines or other CNS depressants for patients in whom alternative treatment options are inadequate; use lowest effective dosages and shortest possible duration of concomitant therapy and monitor closely for respiratory depression and sedation.238 239 246 700 703 (See Specific Drugs under Interactions.)
Introduction
Opiate agonist; semisynthetic phenanthrene derivative.a
Uses for Hydromorphone Hydrochloride
Acute Pain
Used parenterally or orally as conventional preparations (immediate-release tablets, oral solution) for relief of pain that is severe enough to require an opiate analgesic and for which alternative treatments (e.g., nonopiate analgesics, opiate-containing fixed combinations) have not been, or are not expected to be, adequate or tolerated.238 239
Usually, temporary relief of moderate to severe pain such as that associated with acute and some chronic medical disorders including renal or biliary colic, acute trauma, postoperative pain, and cancer.f
Used to provide analgesia during diagnostic and orthopedic procedures.f
In symptomatic treatment of acute pain, reserve opiate analgesics for pain resulting from severe injuries, severe medical conditions, or surgical procedures, or when nonopiate alternatives for relieving pain and restoring function are expected to be ineffective or are contraindicated.431 432 433 435 Use smallest effective dosage for shortest possible duration since long-term opiate use often begins with treatment of acute pain.411 431 434 435 Optimize concomitant use of other appropriate therapies.432 434 435 (See Managing Opiate Therapy for Acute Pain under Dosage and Administration.)
Use highly concentrated (10-mg/mL) injection only in opiate-tolerant patients who require higher dosages of opiate analgesics (see Highly Concentrated [10-mg/mL] Injection under Dosage and Administration); during treatment with this formulation, patient must remain on around-the-clock opiate therapy.239
Reserve extended-release tablets for use in opiate-tolerant patients with pain severe enough to require long-term, daily, around-the-clock use of an opiate analgesic when alternative treatment options (e.g., nonopiate analgesics, immediate-release opiates) are inadequate or not tolerated; not indicated for as-needed (“prn”) use.246
Chronic Pain
For relief of malignant (cancer) pain and chronic nonmalignant pain.f
Extended-release tablets are used orally in opiate-tolerant patients for management of pain that is severe enough to require long-term, daily, around-the-clock use of an opiate analgesic; reserve for use in patients for whom alternative treatment options (e.g., nonopiate analgesics, immediate-release opiates) are inadequate or not tolerated.246 Do not use on an as-needed (“prn”) basis.246 (See Pain [Oral Treatment with Extended-release Tablets] under Dosage and Administration.)
In the management of severe, chronic pain associated with a terminal illness such as cancer, the principal goal of analgesic therapy is to make the patient relatively pain-free while maintaining as good a quality of life as possible.f
Although consideration of the dependence potential of opiate agonists has often limited their effective use by many clinicians in terminally ill patients with severe, chronic pain, such consideration is irrelevant in the context of terminal illness.f
Generally use opiates for management of chronic pain (i.e., pain lasting >3 months or past the time of normal tissue healing410 411 412 413 ) that is not associated with active cancer treatment, palliative care, or end-of-life care only if other appropriate nonpharmacologic and nonopiate pharmacologic strategies have been ineffective and expected benefits for both pain relief and functional improvement are anticipated to outweigh risks.411 412 413 414 422 429
If used for chronic pain, opiate analgesics should be part of an integrated approach that also includes appropriate nonpharmacologic modalities (e.g., cognitive-behavioral therapy, relaxation techniques, biofeedback, functional restoration, exercise therapy, certain interventional procedures) and other appropriate pharmacologic therapies (e.g., nonopiate analgesics, analgesic adjuncts such as selected anticonvulsants and antidepressants for certain neuropathic pain conditions).411 412 413 422 429
Available evidence insufficient to determine whether long-term opiate therapy for chronic pain results in sustained pain relief or improvements in function and quality of life411 423 431 432 436 or is superior to other pharmacologic or nonpharmacologic treatments.432 Use is associated with serious risks (e.g., opiate use disorder [OUD], overdose).411 431 436 (See Managing Opiate Therapy for Chronic Noncancer Pain under Dosage and Administration.)
Related/similar drugs
gabapentin, acetaminophen, tramadol, cyclobenzaprine, naproxen, oxycodone, Tylenol
Hydromorphone Hydrochloride Dosage and Administration
General
Managing Opiate Therapy for Acute Pain
-
Optimize concomitant use of other appropriate therapies.432 434 435
-
When opiate analgesia required, use conventional (immediate-release) opiates in smallest effective dosage and for shortest possible duration, since long-term opiate use often begins with treatment of acute pain.411 431 434 435
-
Consider prescribing naloxone concomitantly for patients who are at increased risk of opiate overdosage411 431 750 or who have household members, including children, or other close contacts who are at risk for accidental ingestion or overdosage.750 (See Respiratory Depression under Cautions.)
-
When sufficient for pain management, use lower-potency opiate analgesics given in conjunction with acetaminophen or an NSAIA on as-needed (“prn”) basis.432
-
For acute pain not related to trauma or surgery, limit prescribed quantity to amount needed for expected duration of pain severe enough to require opiate analgesia (generally ≤3 days and rarely >7 days).411 433 434 435 Do not prescribe larger quantities for use in case pain continues longer than expected;411 432 instead, reevaluate patient if severe acute pain does not remit.411 431 435
-
For moderate to severe postoperative pain, provide opiate analgesic as part of a multimodal regimen that also includes acetaminophen and/or NSAIAs and other pharmacologic (e.g., certain anticonvulsants, regional local anesthetic techniques) and nonpharmacologic therapy as appropriate.430 431 432
-
Oral administration of conventional opiate analgesics generally preferred over IV administration in postoperative patients who can tolerate oral therapy.430 431
-
Scheduled (around-the-clock) dosing frequently is required during immediate postoperative period or following major surgery.430 432 When repeated parenteral administration is required, IV patient-controlled analgesia (PCA) generally is recommended.430 431
Managing Opiate Therapy for Chronic Noncancer Pain
-
Although specific recommendations may vary, common elements in clinical guideline recommendations include risk mitigation strategies, upper dosage thresholds, careful dosage titration, and consideration of risks associated with particular opiates and formulations, coexisting diseases, and concomitant drug therapy.410 411 414 415 423
-
Prior to initiating therapy, thoroughly evaluate patient; assess risk factors for misuse, abuse, and addiction;411 412 413 415 422 429 establish treatment goals (including realistic goals for pain and function); and consider how therapy will be discontinued if benefits do not outweigh risks.411 415
-
Regard initial opiate therapy for chronic noncancer pain as a therapeutic trial that will be continued only if there are clinically meaningful improvements in pain and function that outweigh treatment risks.411 412 413
-
Prior to and periodically during therapy, discuss with patients known risks and realistic benefits and patient and clinician responsibilities for managing therapy.411 412 413 414 415
-
Some experts recommend initiating opiate therapy for chronic noncancer pain with conventional (immediate-release) opiate analgesics prescribed at lowest effective dosage.411 415 Individualize opiate selection, initial dosage, and dosage titration based on patient’s health status, prior opiate use, attainment of therapeutic goals, and predicted or observed harms.412 413
-
Evaluate benefits and harms within 1–4 weeks following initiation of therapy or dosage increase411 413 and reevaluate on ongoing basis (e.g., at least every 3 months411 ) throughout therapy.411 412 413 Document pain intensity and level of functioning and assess progress toward therapeutic goals, presence of adverse effects, and adherence to prescribed therapies.412 413 422 423 Anticipate and manage common adverse effects (e.g., constipation, nausea and vomiting, cognitive and psychomotor impairment).412 413 415 If benefits do not outweigh harms, optimize other therapies and taper opiate to lower dosage or taper and discontinue opiate.411 412 413 415
-
When repeated dosage increases required, evaluate potential causes and reassess relative benefits and risks.412 413 Although evidence is limited, some experts state that opiate rotation may be considered in patients with intolerable adverse effects or inadequate benefit despite dosage increases.412 413 415
-
Higher dosages require particular caution,410 412 415 including more frequent and intensive monitoring or referral to specialist.411 412 413 Greater benefits of high-dose opiates for chronic pain not established in controlled clinical studies; higher dosages associated with increased risks (motor vehicle accidents, overdosage, OUD).411 415 423 424 425 426
-
CDC states that primary care clinicians should carefully reassess individual benefits and risks before prescribing dosages equivalent to ≥50 mg of morphine sulfate daily (approximately ≥12.5 mg of hydromorphone hydrochloride daily) for chronic pain and should avoid dosages equivalent to ≥90 mg of morphine sulfate daily (approximately ≥22.5 mg of hydromorphone hydrochloride daily) or carefully justify decision to prescribe such dosages.411 Other experts recommend consulting a pain management specialist before exceeding a dosage equivalent to 80–120 mg of morphine sulfate daily.423 431 Some states have established opiate dosage thresholds (e.g., maximum daily dosages that can be prescribed, dosage thresholds at which consultation with specialist is mandated or recommended)411 420 421 423 or have mandated risk-management strategies (e.g., review of state prescription drug monitoring program [PDMP] data prior to prescribing).411 419 423
-
Recommended strategies for managing risks include written treatment agreements or plans (e.g., “contracts”), urine drug testing, review of state PDMP data, and risk assessment and monitoring tools.410 411 412 413 414 415 422 423 429
-
Taper and discontinue opiate therapy if patient engages in serious or repeated aberrant drug-related behaviors or drug abuse or diversion.412 413 415 Offer or arrange treatment for patients with OUD.411 412 413
-
Consider prescribing naloxone concomitantly for patients who are at increased risk of opiate overdosage411 431 750 or who have household members, including children, or other close contacts who are at risk for accidental ingestion or overdosage.750 (See Respiratory Depression under Cautions.)
Administration
Administer orally or by sub-Q, IM, or slow IV injection or infusion.238 239 246 a Has been administered IV via a controlled-delivery device for patient-controlled analgesia (PCA). Has been administered epidurally† [off-label].240 241 244
Oral Administration
Administer orally as conventional (immediate-release) or extended-release tablets or as an oral solution.238 246
Use caution when prescribing or dispensing to avoid inadvertent interchange of 8-mg extended-release tablets and 8-mg conventional tablets.246
Conventional Tablets
Conventional tablets and oral solution are bioequivalent.238
Food may decrease rate and extent of absorption of conventional tablets (see Food under Pharmacokinetics), but effects may not be clinically important.238
Oral Solution
Use caution when prescribing or dispensing to avoid confusion between mg and mL.238 When writing prescriptions, specify the intended total dose (in mg) along with the corresponding total volume (in mL).238
Always use a calibrated measuring device to ensure that the oral solution dose is measured and administered accurately; do not use a household teaspoon or tablespoon.238
Oral solution and conventional tablets are bioequivalent.238
Extended-release Tablets
Only clinicians who are knowledgeable in the use of potent opiates for the management of chronic pain should prescribe the extended-release tablets.246
Discontinue all other extended-release opiates when initiating therapy with extended-release hydromorphone.246
Administer once every 24 hours.246
Swallow tablets intact; do not break, crush, dissolve, or chew.246 Ingestion of broken, crushed, chewed, or dissolved tablets may result in rapid drug release and absorption of a potentially fatal dose.246
Administer without regard to food.246
Do not administer with alcohol.246 (See Specific Drugs under Interactions.)
Parenteral Administration
Administer by sub-Q, IM, or slow (over at least 2–3 minutes depending on dose) IV injection.239
Has been administered by continuous IV or sub-Q infusion in selected opiate-tolerant patients with chronic pain; use extreme caution when administering continuous infusions of opiates to patients with no prior exposure to opiate analgesics.240 241 242 243 244
Also administered IV via controlled-delivery device for PCA.241
IM administration of opiate analgesics is discouraged; IM injections can cause pain and are associated with unreliable absorption, resulting in inconsistent analgesia.241 430
Highly Concentrated (10-mg/mL) Injection
Injection is commercially available in various concentrations (0.2, 1, 2, 4, and 10 mg/mL).239 251 Use the 10-mg/mL injection only in patients who are tolerant to and already receiving high dosages of opiate agonists.239 (See Boxed Warning.)
Patients are considered opiate tolerant if they have been receiving at least 60 mg of oral morphine sulfate daily, 25 mcg of transdermal fentanyl per hour, 30 mg of oral oxycodone hydrochloride daily, 60 mg of oral hydrocodone bitartrate daily, 8 mg of oral hydromorphone hydrochloride daily, 25 mg of oral oxymorphone hydrochloride daily, or an equianalgesic dosage of another opiate daily for ≥1 week.239 246
Confusion between the different concentrations or between mg and mL can result in accidental overdosage and death.239
Take care to ensure that correct dosages are prescribed and dispensed.239
Use the 10-mg/mL injection only when required volume can be accurately measured.239 a Reserve for patients who require the reduced total volume and higher concentration of this formulation.239
Dilution
If using the 500-mg single-use (10-mg/mL) vial to prepare an IV infusion solution, withdraw appropriate amount and then discard any unused portion in an appropriate manner.239
Has been diluted (e.g., to a concentration of 1 mg/mL) in 5% dextrose or 0.9% sodium chloride injection for continuous IV infusion in critically ill adult patients.242
Rate of IV Administration
If rapid onset and shorter duration of analgesia are required, may give IV at slow rate (over at least 2–3 minutes depending on dose), with special attention to the possibility of respiratory depression and hypotension.239 a
IV injection for PCA: Self-administered intermittently as needed (“prn”) via controlled-delivery device, with usual lockout intervals (minimum time between self-administered doses programmed into device) of 5–10 minutes.241
Standardize 4 Safety
Standardized concentrations for hydromorphone have been established through Standardize 4 Safety (S4S), a national patient safety initiative to reduce medication errors, especially during transitions of care. Because recommendations from the S4S panels may differ from the manufacturer’s prescribing information, caution is advised when using concentrations that differ from labeling, particularly when using rate information from the label.249 250 For additional information on S4S (including updates that may be available), see [Web].
Concentration standard for adults is for continuous infusions not delivered by a PCA device. Concentration standard for pediatric patients also is for continuous infusions and not for delivery via PCA device.
Patient Population |
Concentration Standard |
Dosing Units |
---|---|---|
Adults |
0.2 mg/mL |
mg/hour |
1 mg/mL |
||
5 mg/mL (based on high dose requirements) |
||
Pediatric patients (<50 kg) |
0.2 mg/mL |
mg/kg/hr |
1 mg/mL |
||
5 mg/mL |
Patient Population |
Concentration Standard |
Dosing Units |
---|---|---|
Adults |
0.2 mg/mL |
mg |
1 mg/mL(caution is advised if both hydromorphone and morphine are used to avoid confusion in selection as both have the same concentration) |
||
10 mg/mL (sub-Q only) |
||
Pediatric patients (<50 kg) |
0.05 mg/mL |
mg/kg/hr |
0.2 mg/mL |
||
1 mg/mL(caution is advised if both hydromorphone and morphine are used to avoid confusion in selection as both have the same concentration) |
Patient Population |
Concentration Standard |
---|---|
Adults |
10 mcg/mL |
Pediatric patients (<50 kg) |
5 mcg/mL |
10 mcg/mL |
Drug Combinations |
Anesthetic Concentration |
Narcotic Concentration |
---|---|---|
Bupivacaine with hydromorphone |
1. Bupivacaine 0.0625% |
1. Hydromorphone 10 mcg/mL |
2. Bupivacaine 0.125% |
2. Hydromorphone 10 mcg/mL |
|
Ropivacaine with hydromorphone |
1. Ropivacaine 0.2% |
1. Hydromorphone 10 mcg/mL |
Drug Combinations |
Anesthetic Concentration |
Narcotic Concentration |
---|---|---|
Bupivacaine with hydromorphone |
1. Bupivacaine 0.0625% |
1. Hydromorphone 5 mcg/mL |
2. Bupivacaine 0.0625% |
2. Hydromorphone 10 mcg/mL |
|
3. Bupivacaine 0.125% |
3. Hydromorphone 5 mcg/mL |
|
4. Bupivacaine 0.125% |
4. Hydromorphone 10 mcg/mL |
|
Ropivacaine with hydromorphone |
1. Ropivacaine 0.1% |
1. Hydromorphone 5 mcg/mL |
2. Ropivacaine 0.1% |
2. Hydromorphone 10 mcg/mL |
|
3. Ropivacaine 0.2% |
3. Hydromorphone 5 mcg/mL |
|
4. Ropivacaine 0.2% |
4. Hydromorphone 10 mcg/mL |
Dosage
Available as hydromorphone hydrochloride; dosage expressed in terms of the salt.238 239
Use lowest effective dosage and shortest duration of therapy consistent with treatment goals of the patient.411 413 431 432 435
Reduce dosage in geriatric or debilitated patients and in patients with renal or hepatic impairment.238 239 246 a
When used concomitantly with other CNS depressants, use lowest effective dosages and shortest possible duration of concomitant therapy.700 703 (See Specific Drugs under Interactions.)
Individualize dosage to provide adequate analgesia and minimize adverse effects.238 239 241 246
Appropriate dosage selection and titration are essential to reduce the risk of respiratory depression.238 239 When selecting initial dosage, consider severity of patient’s pain, patient response, prior analgesic treatment experience, and risk factors for addiction, abuse, and misuse.238 239 246
Because of substantial interpatient variability in relative potency of opiate analgesics and analgesic formulations, it is preferable to underestimate the patient's 24-hour opiate requirements when converting from other opiates to hydromorphone than to overestimate the requirements and manage an adverse reaction.238 239 246
Monitor closely for respiratory depression, especially during the first 24–72 hours of therapy and following any increase in dosage.238 239 246
Continually reevaluate for adequacy of pain control and for adverse effects, as well for development of addiction, abuse, or misuse.238 239 246 During long-term therapy, periodically reevaluate need for continued opiate therapy.246
Frequent communication among the prescriber, other members of the healthcare team, the patient, and the patient's caregiver or family is important during periods of changing analgesic requirements, including the initial dosage titration period.238 239 246
If level of pain increases after dosage stabilization, attempt to identify cause of increased pain before increasing dosage.238 239 246
Avoid abrupt discontinuance to avoid precipitation of withdrawal symptoms.238 239 246 a (See Dependence and Tolerance under Cautions.)
Pediatric Patients
Pain† [off-label] (Treatment with Conventional [Immediate-release] Preparations)
Oral
Children weighing <50 kg: Initially, 0.03–0.08 mg/kg every 3–4 hours as needed.245 437 438 439 440 For severe pain, initial doses of 0.06 mg/kg have been used.241
Children and adolescents weighing ≥50 kg: Initially, 1–2 mg every 3–4 hours as needed.437 439
IV, IM, or Sub-Q
Children weighing <50 kg: Initially, 0.015 mg/kg every 3–6 hours as needed.437 438 439
Children and adolescents weighing ≥50 kg: Initially, 0.2–0.6 mg IV every 2–4 hours or 0.8–1 mg by IM or sub-Q injection every 4–6 hours as needed.437
Adults
Pain (Oral Treatment with Conventional [Immediate-release] Preparations)
Oral
Immediate-release tablets: Usual initial dosage in non-opiate-tolerant adults is 2–4 mg every 4–6 hours.238 240
Oral solution: Usual initial dosage in non-opiate-tolerant adults is 2.5–10 mg every 3–6 hours as needed.238
For severe pain, initial doses of 4–8 mg have been used.241 Adjust dose and/or frequency of administration gradually based on response.238
For chronic pain, administer at regularly scheduled intervals (around the clock); may give supplemental doses of 5–15% of the total daily dosage every 2 hours as needed for breakthrough pain.238
Switching from Other Opiates to Conventional Hydromorphone Preparations
OralConventional tablets: Manufacturer states that safest approach is to initiate hydromorphone hydrochloride at one-half the usual initial dose administered every 4–6 hours.238 Adjust dose and/or frequency of administration based on response.238
Oral solution: Manufacturer states that safest approach is to initiate hydromorphone hydrochloride at one-half the usual initial dose administered every 3–6 hours.238 Adjust dose and/or frequency of administration based on response.238
Pain (Oral Treatment with Extended-release Tablets)
Oral
Use only in opiate-tolerant patients.246 Discontinue all other around-the-clock opiate analgesics when therapy with the extended-release tablets is initiated.246
Patients are considered opiate tolerant if they have been receiving at least 60 mg of oral morphine sulfate daily, 25 mcg of transdermal fentanyl per hour, 30 mg of oral oxycodone hydrochloride daily, 60 mg of oral hydrocodone bitartrate daily, 8 mg of oral hydromorphone hydrochloride daily, 25 mg of oral oxymorphone hydrochloride daily, or an equianalgesic dosage of another opiate daily for ≥1 week.239 246
Switching from Conventional Hydromorphone to Extended-release Hydromorphone
OralAdminister same total daily dosage once every 24 hours.246
Switching from Other Oral Opiates to Extended-release Hydromorphone
OralUse approximate oral conversion factors in Table 6 to calculate estimated daily hydromorphone hydrochloride requirement.246 Recommended initial dosage is 50% of the calculated estimated daily requirement administered once daily (e.g., if total daily oral oxycodone hydrochloride dosage is 60 mg, estimated daily oral hydromorphone hydrochloride requirement would be 24 mg and approximate initial dosage of hydromorphone hydrochloride extended-release tablets would be 12 mg once daily).246
For patients receiving >1 opiate, calculate approximate oral hydromorphone hydrochloride dosage for each opiate separately and then sum the totals; for patients receiving fixed-combination analgesics, consider only the opiate component.246
Always round the calculated dosage down, when necessary, to an appropriate available tablet strength.246
Table 6 is not a table of equianalgesic doses.246 Use the conversion factors in Table 6 only to switch patients from the listed oral opiate analgesics to hydromorphone hydrochloride extended-release tablets; use of the conversion factors to switch patients from hydromorphone hydrochloride extended-release tablets to another opiate will result in overestimation of the dosage of the new opiate and possible fatal overdosage.246
Opiate Agonist |
Approximate Oral Conversion Factor |
---|---|
Hydromorphone hydrochloride |
1 |
Codeine phosphate |
0.06 |
Hydrocodone bitartrate |
0.4 |
Methadone hydrochloride |
0.6 |
Morphine sulfate |
0.2 |
Oxycodone hydrochloride |
0.4 |
Oxymorphone hydrochloride |
0.6 |
Conversion from methadone: Particularly close monitoring required; equianalgesic conversion ratios between methadone and other opiates vary widely depending on extent of prior methadone exposure.246
Switching from Transdermal Fentanyl to Extended-release Hydromorphone
OralEstimated equianalgesic dosage of extended-release hydromorphone hydrochloride is 12 mg every 24 hours for each 25-mcg/hour increment in fentanyl transdermal dosage.246
Initiate extended-release hydromorphone hydrochloride at 50% of the calculated total daily dosage.246 Always round the calculated dosage down, when necessary, to an appropriate available tablet strength.246
Can initiate extended-release tablets 18 hours following removal of fentanyl transdermal system.246
Dosage Adjustment to Achieve Adequate Analgesia
OralPatients who experience breakthrough pain may require dosage adjustment or supplemental analgesia (i.e., “rescue” therapy with an immediate-release analgesic).246
Titrate dosage of extended-release tablets in increments of 4–8 mg every 3–4 days based on response.246
In clinical trials, dosage range was 12–64 mg daily.246
Pain (Parenteral Treatment)
Treatment of Opiate-naive Adults
IM or Sub-QInitially 1–2 mg every 2–3 hours as needed.239 Some patients may require lower initial dosages.239 Adjust dose and/or frequency of administration based on response.239
IVInitially 0.2–1 mg by slow injection every 2–3 hours.239 Some patients may require lower initial dosages.239 Adjust dose and/or frequency of administration gradually based on response.239
Treatment of Critically Ill Adults
IVIn ICU setting, loading dose of 0.2–0.6 mg followed by continuous infusion of 0.5–3 mg/hour has been used.242
Has been administered in intermittent IV doses of 10–30 mcg/kg every 1–2 hours or as continuous IV infusion of 7–15 mcg/kg per hour.243
Switching from Other Opiates to Parenteral Hydromorphone
IV, IM, or Sub-QConvert total daily dosage of current opiate to equivalent daily dosage of hydromorphone hydrochloride, then reduce estimated parenteral hydromorphone hydrochloride dosage by one-half because of possible incomplete cross-tolerance; administer in divided doses.239 Adjust dosage based on response.239
Discontinuance of Analgesic Therapy with Hydromorphone
Oral
In patient who may be physically dependent on opiates, generally reduce dosage by no more than 10–25% every 2–4 weeks.238 246 Patients taking opiates for briefer periods of time may tolerate more rapid taper.238 246
Monitor for manifestations of opiate withdrawal, adequacy of pain control, changes in mood, and emergence of suicidal thoughts during dosage taper.238 246 (See Dependence and Tolerance under Cautions.) If manifestations of withdrawal occur, may need to pause the taper or increase dosage to prior level before tapering dosage more slowly.238 246
IV, IM, or Sub-Q
In patient who may be physically dependent on opiates, manufacturer recommends reducing dosage by 25–50% every 2–4 days.239
If manifestations of withdrawal occur, increase dosage to prior level and taper more slowly (i.e., increase interval between dosage reductions and/or reduce amount of each incremental change in dose).239
Prescribing Limits
Adults
Pain
For acute pain not related to trauma or surgery, limit prescribed quantity to amount needed for the expected duration of pain severe enough to require opiate analgesia (generally ≤3 days and rarely >7 days).411 433 434 435
CDC recommends that primary care clinicians carefully reassess individual benefits and risks before prescribing dosages equivalent to ≥50 mg of morphine sulfate daily (approximately ≥12.5 mg of hydromorphone hydrochloride daily) for chronic pain and avoid dosages equivalent to ≥90 mg of morphine sulfate daily (approximately ≥22.5 mg of hydromorphone hydrochloride daily) or carefully justify their decision to prescribe such dosages.411 Other experts recommend consulting a pain management specialist before exceeding a dosage equivalent to 80–120 mg of morphine sulfate daily.423 431
Some states have set prescribing limits (e.g., maximum daily dosages that can be prescribed, dosage thresholds at which consultation with a specialist is mandated or recommended).411 420 421 423
Special Populations
Hepatic Impairment
Pain
Oral (Conventional [Immediate-release] Preparations)
Depending on degree of impairment, reduce initial dosage to one-fourth to one-half the usual recommended dosage.238
Reduce initial dosage in patients with moderate hepatic impairment (Child-Pugh class B); use even more conservative dosages in patients with severe hepatic impairment (Child-Pugh class C).238 246
Closely monitor during dosage titrations.238
Oral (Extended-release Tablets)
Reduce initial dosage in patients with moderate hepatic impairment to one-fourth the usual recommended dosage.246
Closely monitor during initiation of therapy and dosage titrations.246
Use of alternative analgesic preparations recommended in those with severe hepatic impairment.246
IV, IM, or Sub-Q
Reduce initial dosage in patients with moderate hepatic impairment to one-fourth to one-half the usual recommended dosage; consider likelihood that systemic exposure will be further increased when selecting initial dosage in patients with severe hepatic impairment.239
Closely monitor during dosage titrations.239
Renal Impairment
Pain
Oral (Conventional [Immediate-release] Preparations)
Depending on degree of impairment, reduce initial dosage to one-fourth to one-half the usual recommended dosage.238
Reduce initial dosage in patients with moderate renal impairment (Clcr 40–60 mL/minute); further reduce dosage in those with severe renal impairment (Clcr <30 mL/minute).238
Closely monitor during dosage titrations.238
Oral (Extended-release Tablets)
Reduce initial dosage in patients with moderate renal impairment to one-half the usual recommended dosage.246
Closely monitor during initiation of therapy and dosage titrations.246
Because extended-release tablets are intended for once-daily administration, consider an alternative analgesic regimen with flexible dosing interval in patients with severe renal impairment.246
IV, IM, or Sub-Q
Depending on degree of impairment, reduce initial dosage to one-fourth to one-half the usual recommended dosage.239
Closely monitor during dosage titrations.239
Geriatric and Debilitated Patients
Select dosage with caution, and use lower than usual initial dosages.238 239 246 a
May reduce IV dose to 0.2 mg.239
Cautions for Hydromorphone Hydrochloride
Contraindications
-
Known hypersensitivity (e.g., anaphylaxis) to hydromorphone or any ingredient in the formulation.238 239 246
-
Acute or severe bronchial asthma in unmonitored settings or in the absence of resuscitative equipment.238 239 246
-
Known or suspected GI obstruction, including paralytic ileus.238 239 246 Because extended-release tablets are nondeformable, contraindications for this formulation also include blind loops in GI tract and prior surgery or underlying disease that would cause narrowing of GI tract.246 (See GI Complications with Extended-release Tablets under Cautions.)
-
Extended-release tablets and 10-mg/mL injection are contraindicated in patients not already tolerant to opiate agonists.239 246
Warnings/Precautions
Warnings
Use of Highly Concentrated Injection
Use 10-mg/mL injection only in patients who are tolerant to opiate agonists; overdosage and/or death may result if confused with less concentrated formulations and used in patients who are not tolerant to opiate agonists.239
Use extreme caution to avoid confusing the highly concentrated injection with the less concentrated injections.239
Dosing Errors with Oral Solution
Dosing errors can result in accidental overdosage and death.238 Ensure that the dose is clearly communicated and accurately dispensed.238 (See Oral Solution under Dosage and Administration.) Always use a calibrated measuring device to accurately measure and administer the oral solution.238
Use of Extended-release Tablets
Use the extended-release tablets only in patients who are tolerant to opiate agonists; fatal respiratory depression may result if used in patients who are not tolerant to opiate agonists.246
Do not break, chew, crush, inject, or dissolve extended-release tablets as rapid release of drug and absorption of a potentially fatal dose may occur.246
Addiction, Abuse, and Misuse
Risk of addiction, abuse, and misuse, which can lead to overdosage and death.238 239 246 Addiction can occur at recommended dosages or with misuse or abuse.238 239 246 Concurrent abuse of alcohol and other CNS depressants increases risk of toxicity.238 239 246 Abuse potential similar to that of other potent opiate agonists.238 239 246
Modified-release (e.g., extended-release) opiates are associated with a greater risk of overdose and death because of the larger amount of drug contained in each dosage unit.246
Abuse or misuse of hydromorphone extended-release tablets by crushing or chewing the tablets, snorting the contents, or injecting the dissolved contents will result in uncontrolled delivery of hydromorphone and can result in a fatal overdose.246 IV injection of tablet excipients can result in local tissue necrosis, infection, pulmonary granulomas, embolism, and death and can increase the risk of endocarditis and valvular heart injury.246
Assess each patient’s risk for addiction, abuse, and misuse prior to prescribing; monitor all patients for development of these behaviors or conditions.238 239 246 Personal or family history of substance abuse (drug or alcohol addiction or abuse) or mental illness (e.g., major depression) increases risk.238 239 246
The potential for addiction, abuse, and misuse should not prevent opiate prescribing for appropriate pain management, but does necessitate intensive counseling about risks and proper use and intensive monitoring for signs of addiction, abuse, and misuse.238 239 246
Prescribe only in the smallest appropriate quantity and instruct patients on secure storage and proper disposal to prevent theft.238 239 246
When opiate analgesics are being discontinued because of a suspected substance use disorder (SUD), evaluate and treat the patient or refer for evaluation and treatment of SUD.238 246
Respiratory Depression
Serious, life-threatening, or fatal respiratory depression can occur with use of opiates, even when used as recommended; can occur at any time during therapy, but risk is greatest during initiation of therapy and following dosage increases.238 239 246 Monitor for respiratory depression, especially during first 24–72 hours of therapy and following any dosage increase.238 239 246
Carbon dioxide retention from opiate-induced respiratory depression can exacerbate the drug's sedative effects and, in certain patients, can lead to elevated intracranial pressure.238 239 246 (See Head Injury and Increased Intracranial Pressure under Cautions.)
Opiates can cause sleep-related breathing disorders, including central sleep apnea and sleep-related hypoxemia.238 239 246 Risk of central sleep apnea is dose dependent; consider tapering opiate dosage if central sleep apnea occurs.238 239 246
Geriatric, cachectic, or debilitated patients are at increased risk for life-threatening respiratory depression.238 239 246 Closely monitor such patients, particularly following initiation of therapy, during dosage titration, and during concomitant therapy with other respiratory depressants.238 239 246 Consider use of nonopiate analgesics.238 239 246
Even recommended doses of hydromorphone may decrease respiratory drive to the point of apnea in patients with COPD, cor pulmonale, substantially decreased respiratory reserve, hypoxia, hypercapnia, or preexisting respiratory depression.238 239 246 Closely monitor such patients, particularly following initiation of therapy, during dosage titration, and during concomitant therapy with other respiratory depressants.238 239 246 Consider use of nonopiate analgesics.238 239 246 (See Contraindications under Cautions.)
Appropriate dosage selection and titration are essential to reduce the risk of respiratory depression.238 239 246 Overestimation of the dosage when transferring patients from another opiate analgesic can result in fatal overdosage with the first dose.238 239 246
Accidental ingestion of even 1 dose, especially by a child, can result in respiratory depression and fatal overdosage.238 246
If respiratory depression occurs, follow usual guidelines for management of opiate agonist-induced respiratory depression.238 239 246
Routinely discuss availability of the opiate antagonist naloxone with all patients receiving new or reauthorized prescriptions for opiate analgesics, including hydromorphone.750
Consider prescribing naloxone for patients receiving opiate analgesics who are at increased risk of opiate overdosage (e.g., those receiving concomitant therapy with benzodiazepines or other CNS depressants, those with history of opiate or substance use disorder, those with medical conditions that could increase sensitivity to opiate effects, those who have experienced a prior opiate overdose)411 431 750 or who have household members, including children, or other close contacts who are at risk for accidental ingestion or overdosage.750 Even if patients are not receiving an opiate analgesic, consider prescribing naloxone if the patient is at increased risk of opiate overdosage (e.g., those with current or past diagnosis of OUD, those who have experienced a prior opiate overdose).750
Concomitant Use with Benzodiazepines or Other CNS Depressants
Concomitant use of opiates, including hydromorphone, and benzodiazepines or other CNS depressants (e.g., anxiolytics, sedatives, hypnotics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opiate agonists, alcohol) may result in profound sedation, respiratory depression, coma, and death.416 417 418 700 701 702 703 Substantial proportion of fatal opiate overdoses involve concurrent benzodiazepine use.416 417 418 435 700 701
Reserve concomitant use of hydromorphone and other CNS depressants for patients in whom alternative treatment options are inadequate.700 703 (See Specific Drugs under Interactions.)
Sensitivity Reactions
Sulfite Sensitivity
Some formulations contain sulfites, which may cause allergic-type reactions (including anaphylaxis and life-threatening or less severe asthmatic episodes) in certain susceptible individuals.238 239 246 a
Latex Sensitivity
Packaging components for some formulations may contain natural latex proteins in the form of dry natural rubber and/or natural rubber latex; take appropriate precautions for patients with a history of natural latex sensitivity.a
Other Warnings and Precautions
General Opiate Agonist Precautions
Shares the toxic potentials of the opiate agonists; observe the usual precautions of opiate agonist therapy.a
Adrenal Insufficiency
Adrenal insufficiency reported in patients receiving opiate agonists or opiate partial agonists.400 Manifestations are nonspecific and may include nausea, vomiting, anorexia, fatigue, weakness, dizziness, and hypotension.400
If adrenal insufficiency is suspected, perform appropriate laboratory testing promptly and provide physiologic (replacement) dosages of corticosteroids; taper and discontinue the opiate agonist or partial agonist to allow recovery of adrenal function.400 If the opiate agonist or partial agonist can be discontinued, perform follow-up assessment of adrenal function to determine if corticosteroid replacement therapy can be discontinued.400 In some patients, switching to a different opiate improved symptoms.400
Hypotension
May cause severe hypotension, including orthostatic hypotension and syncope, in ambulatory patients, especially in individuals whose ability to maintain their BP is compromised by depleted blood volume or concomitant use of certain CNS depressants (e.g., phenothiazines, general anesthetics).238 239 246 Monitor BP following initiation of therapy and dosage increases in such patients.238 239 246 (See Specific Drugs under Interactions.)
Vasodilation produced by the drug may further reduce cardiac output and BP in patients with circulatory shock.238 239 246 Avoid use in such patients.238 239 246
Head Injury and Increased Intracranial Pressure
Potential for increased carbon dioxide retention and secondary elevation of intracranial pressure; in patients particularly susceptible to these effects (e.g., those with evidence of elevated intracranial pressure or brain tumors), monitor closely for sedation and respiratory depression, particularly during initiation of therapy.238 239 246
Opiates may obscure the clinical course in patients with head injuries.238 239 246
Avoid use in patients with impaired consciousness or coma.238 239 246
Acute Abdominal Conditions
Contraindicated in patients with known or suspected GI obstruction, including paralytic ileus.238 239 246
GI Complications with Extended-release Tablets
Extended-release tablets are nondeformable and do not appreciably change shape in the GI tract; obstructive symptoms reported in patients with or at risk for GI strictures (e.g., because of prior GI surgery) who ingested nondeformable extended-release drug formulations.246
Hydromorphone extended-release tablets contraindicated in patients with GI obstruction or with severe narrowing of the GI tract due to any pathologic or iatrogenic condition (e.g., esophageal motility disorders, small bowel inflammatory disease, short-gut syndrome due to adhesions or decreased transit time, history of peritonitis, cystic fibrosis, chronic intestinal pseudo-obstruction, Meckel’s diverticulum).246
Extended-release tablets may be visible on abdominal radiographs under certain circumstances, especially when digital enhancing techniques are utilized.246
Pancreatic and Biliary Disease
May cause spasm of the sphincter of Oddi and increase serum amylase concentrations; monitor patients with biliary disease, including acute pancreatitis, for worsening symptoms.238 239 246
Seizures
May aggravate preexisting seizures in patients with seizure disorders.238 239 246 Monitor for worsened seizure control.238 239 246
May increase risk of seizures in other settings associated with seizures.238 239 246
Dependence and Tolerance
Physical dependence and tolerance can develop during prolonged opiate therapy.238 239 246
Rapid or abrupt discontinuance of opiates in physically dependent patients has resulted in serious withdrawal symptoms (e.g., restlessness, lacrimation, rhinorrhea, yawning, sweating, chills, myalgia, mydriasis, irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, increased BP, respiratory rate, or heart rate), uncontrolled pain, suicide, attempts to find other sources of opiate analgesics, and attempts to treat pain or withdrawal symptoms with illicit substances.238 239 246
Gradually taper dosage when discontinuing opiates in patients who may be physically dependent; consider dosage and treatment duration, type of pain, and physical and psychologic attributes of patient.238 246 (See Discontinuance of Analgesic Therapy with Hydromorphone under Dosage and Administration.) Ensure ongoing care of patient and agree on tapering schedule and follow-up plan with clear and realistic goals and expectations.238 246
Ensure that a multimodal approach to pain management is in place prior to initiating an opiate taper, particularly for patients receiving high dosages and/or long-term opiate therapy for chronic pain.238 246
Avoid concomitant use of opiate partial agonists.238 239 246 (See Specific Drugs under Interactions.)
Infants born to women who are physically dependent on opiates also will be physically dependent and may exhibit respiratory difficulties and manifestations of opiate withdrawal.238 239 246 (See Pregnancy under Cautions.)
CNS Depression
May impair mental alertness or physical coordination; warn patient to avoid driving or operating machinery until effects on individual are known.238 239 246
Concurrent use with other CNS depressants may result in profound sedation, respiratory depression, coma, or death.700 703 (See Specific Drugs under Interactions.)
Hypogonadism
Hypogonadism or androgen deficiency reported in patients receiving long-term opiate agonist or opiate partial agonist therapy;400 401 402 403 404 causality not established.400 Manifestations may include decreased libido, impotence, erectile dysfunction, amenorrhea, or infertility.400 Perform appropriate laboratory testing in patients with manifestations of hypogonadism.400
Local Effects of Concentrated Injection
Consider possibility of local irritation and induration with IM or sub-Q use of 10-mg/mL injection.a
Specific Populations
Pregnancy
No available data in pregnant women to inform a drug-associated risk for major birth defects and spontaneous abortion.238 239 246 Neural tube defects, soft tissue and skeletal abnormalities, reduced postnatal pup survival, developmental delays, and altered behavioral responses observed in animal studies with hydromorphone.238 239 246
Analysis of data from the National Birth Defects Prevention Study (large population-based, case-control study) suggests therapeutic use of opiates in pregnant women during organogenesis is associated with a low absolute risk of birth defects, including heart defects, spina bifida, and gastroschisis.253 254
Use of opiates in pregnant women during labor can result in neonatal respiratory depression and psychophysiologic effects.238 239 246 Monitor neonates whose mothers received opiates for respiratory depression; opiate antagonist must be readily available for reversal of respiratory depression.238 239 246 Hydromorphone is not recommended for use in pregnant women during and immediately before labor.238 239 246
Prolonged maternal use of opiates during pregnancy can result in neonatal opiate withdrawal syndrome; in contrast to adults, withdrawal syndrome in neonates may be life-threatening and requires management according to protocols developed by neonatology experts.238 239 246 a Syndrome presents with irritability, hyperactivity and abnormal sleep pattern, high-pitched cry, tremor, vomiting, diarrhea, and failure to gain weight.238 239 246 a Onset, duration, and severity vary depending on the specific opiate used, duration of use, timing and amount of last maternal use, and rate of drug elimination by the neonate.238 239 246 a
Lactation
Distributed into milk in low concentrations.238 239 246
Consider developmental and health benefits of breast-feeding along with the mother's clinical need for hydromorphone and any potential adverse effects on the breast-fed infant from the drug or underlying maternal condition.238 239 Manufacturer states that women receiving hydromorphone extended-release tablets should not breast-feed infants.246
Monitor infants exposed to hydromorphone for excessive sedation and respiratory depression.238 239 246
Symptoms of withdrawal can occur in opiate-dependent breast-fed infants upon cessation of maternal opiate use or cessation of breast-feeding by women receiving hydromorphone.238 239 246
Pediatric Use
Safety and efficacy not established in children;238 239 246 however, conventional preparations of hydromorphone have been used in children.245 437 438 439 440 (See Pediatric Patients under Dosage and Administration.)
Geriatric Use
Possible increased sensitivity to the drug's effects.238 239 246 Increased risk of respiratory depression.238 239 246
Select dosage with caution; usually initiate therapy at low end of dosage range and titrate slowly with close monitoring for CNS or respiratory depression.238 239 246
Consider greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or drug therapy in geriatric patients.238 239 246 Possible increased risk of adverse reactions in patients with renal impairment.238 239 246 May be useful to monitor renal function.238 239 246
Hepatic Impairment
Exposure to drug may be increased.238 239 246 (See Absorption: Special Populations, under Pharmacokinetics.) Use conservative initial dosage and monitor closely for CNS or respiratory depression.238 239 246 (See Hepatic Impairment under Dosage and Administration.)
Renal Impairment
Exposure to drug may be increased.238 239 246 (See Absorption: Special Populations, under Pharmacokinetics.) Use conservative initial dosage and monitor closely for CNS or respiratory depression.238 239 246 (See Renal Impairment under Dosage and Administration.)
Common Adverse Effects
Lightheadedness, dizziness, sedation, nausea, vomiting, sweating, flushing, dysphoria, euphoria, dry mouth, pruritus.238 239
With extended-release tablets for chronic pain: Constipation, nausea, vomiting, somnolence, headache, dizziness.246
Drug Interactions
Minimal potential to inhibit CYP isoenzymes 1A2, 2C9, 2C19, 2D6, 3A4, and 4A11.246
Drugs Associated with Serotonin Syndrome
Risk of serotonin syndrome when used with other serotonergic drugs.400 Examples include serotonin type 1 (5-HT1) receptor agonists (“triptans”), SSRIs, SNRIs, tricyclic antidepressants, antiemetics that are 5-HT3 receptor antagonists, buspirone, cyclobenzaprine, dextromethorphan, lithium, metaxalone, St. John’s wort (Hypericum perforatum), tryptophan, other serotonin modulators (e.g., mirtazapine, nefazodone, trazodone, vilazodone), and MAO inhibitors (those used to treat psychiatric disorders and others [e.g., linezolid, methylene blue, selegiline]).238 239 400
May occur at usual dosages.400 Symptom onset generally occurs within several hours to a few days of concomitant use, but may occur later, particularly after dosage increases.400 (See Advice to Patients.)
If concomitant use of other serotonergic drugs is warranted, monitor patients for serotonin syndrome, particularly during initiation of therapy and dosage increases.400
If serotonin syndrome is suspected, discontinue hydromorphone, other opiate therapy, and/or any concurrently administered serotonergic agents.400
Specific Drugs
Drug |
Interaction |
Comments |
---|---|---|
Amphetamine |
Dextroamphetamine may enhance opiate agonist analgesiaf |
|
Anticholinergics |
Possible increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus239 246 |
Monitor for urinary retention or reduced gastric motility238 239 |
Antidepressants, tricyclic (TCAs) |
Opiates may potentiate the effects of TCAsf See also Drugs Associated with Serotonin Syndrome under Interactions |
Use concomitantly with caution; dosage adjustment may be necessaryf |
Benzodiazepines |
Risk of profound sedation, respiratory depression, hypotension, coma, or death238 239 416 417 418 700 701 703 |
Whenever possible, avoid concomitant use410 411 415 435 Use concomitantly only if alternative treatment options are inadequate; use lowest effective dosages and shortest possible duration of concomitant therapy700 703 In patients receiving hydromorphone, initiate benzodiazepine, if required for any indication other than epilepsy, at lower dosage than indicated in the absence of opiate therapy and titrate based on clinical response700 703 In patients receiving a benzodiazepine, initiate hydromorphone, if required, at reduced dosage and titrate based on clinical response700 703 Monitor closely for respiratory depression and sedation700 703 Consider prescribing naloxone for patients receiving opiates and benzodiazepines concomitantly411 431 750 |
CNS depressants (e.g., other opiate agonists, alcohol, antipsychotics, anxiolytics, general anesthetics, muscle relaxants, sedatives/hypnotics, tranquilizers) |
Additive CNS and respiratory depressant effects; increased risk of respiratory depression, profound sedation, hypotension, coma, or death238 239 246 f 700 703 Alcohol: Increased peak plasma hydromorphone concentrations with extended-release tablets, possible ingestion of toxic dose246 |
Use concomitantly only if alternative treatment options are inadequate; use lowest effective dosages and shortest possible duration of concomitant therapy700 703 In patients receiving hydromorphone, initiate CNS depressant, if required for any indication other than epilepsy, at lower dosage than indicated in the absence of opiate therapy and titrate based on clinical response700 703 In patients receiving a CNS depressant, initiate hydromorphone, if required, at reduced dosage and titrate based on clinical response700 703 Monitor closely for respiratory depression and sedation700 703 Consider prescribing naloxone for patients receiving opiates and other CNS depressants concomitantly750 |
Diuretics |
Opiate agonists may decrease diuretic efficacy by inducing vasopressin release238 239 |
Monitor for reduced diuretic and/or BP effects; increase diuretic dosage as needed238 239 |
MAO inhibitors (e.g., isocarboxazid, linezolid, methylene blue, phenelzine, selegiline, tranylcypromine) |
Severe, unpredictable potentiation of opiates reported; possible CNS excitation or depression, hypotension or hypertension239 246 See also Drugs Associated with Serotonin Syndrome under Interactions |
Allow14 days to elapse following discontinuance of MAO inhibitor and initiation of hydromorphone239 246 If urgent opiate use required, use test doses and frequent titration of small doses for pain relief while closely monitoring BP and monitoring for CNS and respiratory depression238 239 |
Neuromuscular blocking agents |
May enhance the neuromuscular blocking action of skeletal muscle relaxants and increase respiratory depressant effects238 239 246 f |
Monitor for respiratory depression; reduce dosage of one or both agents as necessary238 239 |
Opiate partial agonists (butorphanol, buprenorphine, nalbuphine, pentazocine) |
Possible reduced analgesic effect and/or withdrawal symptoms238 239 246 f |
Hydromorphone Hydrochloride Pharmacokinetics
Absorption
Bioavailability
Well absorbed following oral, rectal, or parenteral administration.a
Undergoes extensive first-pass metabolism following oral administration.238 Bioavailability following oral administration of a single 8-mg conventional tablet is approximately 24%.238
Peak plasma concentrations attained within 0.5–1 hour or 12–16 hours after oral administration of conventional (immediate-release) preparations or extended-release tablets, respectively.238 246
Systemic exposure is dose proportional over a dose range of 2–8 mg as conventional tablets.238
Conventional tablets and oral solution are bioequivalent.238
Following oral administration as conventional tablets given 4 times daily or as extended-release tablets given once daily at same total daily dosage, steady-state plasma concentrations are maintained within same concentration range; extended-release tablets produce less fluctuation in concentrations.246
Onset
Usually 15–30 minutes with conventional preparations; more rapid than morphine.a
Duration
Maintained for 4–5 hours following administration as conventional preparation, depending on the route; may have shorter duration of action than morphine.a
Food
Conventional tablets: Food decreases peak plasma concentrations and increases systemic exposure by 25 and 35%, respectively, and delays peak plasma concentrations by 0.8 hour.238
Extended-release tablets: Food does not alter pharmacokinetics.246
Special Populations
Hepatic impairment: Systemic exposure after single oral dose is increased fourfold in individuals with moderate impairment (Child-Pugh class B).238 239 Further increase expected in severe hepatic impairment.238 239
Renal impairment: Systemic exposure after single oral dose is increased twofold in individuals with moderate impairment (Clcr 40–60 mL/minute) and threefold to fourfold in those with severe impairment (Clcr <30 mL/minute).238 239
Distribution
Extent
Crosses the placenta.238 239 246 Distributes into breast milk.238 239
Plasma Protein Binding
Approximately 8–19% at therapeutic plasma concentrations.238
Elimination
Metabolism
Principally in the liver via glucuronic acid conjugation to hydromorphone-3-glucuronide (95%); minor amounts of 6-hydroxy reduction metabolites.238 239 246 a
Elimination Route
Excreted principally in the urine as hydromorphone-3-glucuronide.238 239 a
Half-life
Conventional preparations: Approximately 2.3–2.8 hours.238 239
Extended-release tablets: Approximately 11 hours (range: 8–15 hours).246
Special Populations
In severe renal impairment, half-life prolonged to 40 hours.238
Age and sex do not substantially alter pharmacokinetics.238
Stability
Storage
Oral
Conventional Tablets
20–25°C.238 Protect from light.238
Extended-release Tablets
20–25°C.246
Solution
20–25°C.238 Protect from light.238
Parenteral
Affected by light and injection may develop a slight yellowish discoloration; this change apparently does not indicate loss of potency.239 a
Injection
20–25°C (may be exposed to 15–30°C).239 Protect from light.239
Actions
-
A potent analgesic; shares actions of the opiate agonists.238 239 246 a
-
Opiate agonists alter perception of and emotional response to pain.f
-
Precise mechanism of action has not been fully elucidated; opiate agonists act at several CNS sites, involving several neurotransmitter systems to produce analgesia.238 239 246 f
-
Pain perception is altered in the spinal cord and higher CNS levels (e.g., substantia gelatinosa, spinal trigeminal nucleus, periaqueductal gray, periventricular gray, medullary raphe nuclei, hypothalamus).f
-
Opiate agonists do not alter the threshold or responsiveness of afferent nerve endings to noxious stimuli, nor peripheral nerve impulse conduction.f
-
Opiate agonists act at specific receptor binding sites in the CNS and other tissues; opiate receptors are concentrated in the limbic system, thalamus, striatum, hypothalamus, midbrain, and spinal cord.f
-
Agonist activity at the opiate μ- or κ-receptor can result in analgesia, miosis, and/or decreased body temperature.f
-
Agonist activity at the μ-receptor can also result in suppression of opiate withdrawal (and antagonist activity can result in precipitation of withdrawal).f
-
Respiratory depression may be mediated by μ-receptors, possibly μ2-receptors (which may be distinct from μ1-receptors involved in analgesia); κ- and δ-receptors may also be involved in respiratory depression.f
-
May depress the cough reflex by a direct effect on the cough centers in the medulla; cough-suppressant opiate receptors have also been suggested.f
-
Nausea, vomiting, constipation, and euphoria may be less marked with hydromorphone than with morphine.f
Advice to Patients
-
Importance of reading the manufacturer’s patient information (e.g., medication guide) each time the drug is dispensed.238 246
-
Potential for addiction, abuse, and misuse, which can lead to overdosage or death, even when used as recommended.238 246 Protect from theft or misuse; properly dispose of any unused drug.238 246 Do not share hydromorphone with others.238 246
-
Instruct patients on proper measurement of hydromorphone oral solution to ensure appropriate dose is accurately measured and administered.238 Advise patients to always use a calibrated measuring device.238 If the prescribed concentration is changed, instruct patients on how to correctly measure the new dose.238
-
Risk of life-threatening respiratory depression; most likely to occur following initiation of therapy or increase in dosage; may occur at recommended dosages.238 246 750 Importance of seeking immediate medical attention if signs or symptoms of respiratory depression occur.238 246 Advise patients of the benefits of naloxone following opiate overdose and of their options for obtaining the drug.238 750
-
Accidental ingestion, especially by a child, may result in respiratory depression or death.238 246 Instruct patients to keep the drug in a secure location and out of the reach of children.238 246
-
Risk of potentially fatal additive effects (e.g., profound sedation, respiratory depression, coma) if used concomitantly with benzodiazepines or other CNS depressants, including alcohol and other opiates, either therapeutically or illicitly; avoid concomitant use unless such use is supervised by clinician.238 246 700 703
-
Potential risk of serotonin syndrome with concurrent use of hydromorphone and other serotonergic agents.400 Importance of immediately contacting clinician if manifestations of serotonin syndrome (e.g., agitation, hallucinations, tachycardia, labile BP, fever, excessive sweating, shivering, shaking, muscle stiffness, twitching, loss of coordination, nausea, vomiting, diarrhea) develop.400
-
Importance of avoiding concomitant use of MAO inhibitors.238 246
-
Potential risk of adrenal insufficiency.400 Importance of contacting clinician if manifestations of adrenal insufficiency (e.g., nausea, vomiting, loss of appetite, fatigue, weakness, dizziness, hypotension) develop.400
-
Importance of using extended-release tablets exactly as prescribed and only if opiate tolerant.246 Importance of not breaking, cutting, crushing, chewing, or dissolving extended-release tablets; potentially fatal overdose can occur.246
-
To avoid withdrawal symptoms following prolonged therapy, importance of not discontinuing hydromorphone without first discussing a tapering plan with clinician.238 246
-
Risk of GI obstruction with use of hydromorphone extended-release tablets in patients with preexisting severe narrowing of GI tract.246 Importance of informing clinician of prior GI surgeries and GI conditions that may cause narrowing.246 Importance of promptly reporting symptoms of GI obstruction (e.g., abdominal pain or distension, severe constipation, vomiting).246
-
Potential for orthostatic hypotension and syncope to occur.238 246 Inform patients of symptoms of low BP and steps to take if hypotension occurs (e.g., sit or lie down, carefully rise from a seated or supine position).238 246
-
Possibility of anaphylaxis and importance of seeking appropriate medical attention.238 246
-
Potential for fetal harm; importance of women informing their clinician of known or suspected pregnancy.238 246 Importance of clinician informing women that chronic use during pregnancy may result in neonatal opiate withdrawal syndrome, which can be life-threatening if not recognized and treated.238 246
-
Advise nursing women to monitor infants exposed to opiates for increased sleepiness, breathing difficulties, or limpness and to seek immediate medical care if such manifestations occur.238 Advise women that use of extended-release hydromorphone in nursing women is not recommended.246
-
Possible risk (although causality not established) of hypogonadism or androgen deficiency with long-term opiate agonist or partial agonist use.400 Importance of informing clinician if decreased libido, impotence, erectile dysfunction, amenorrhea, or infertility occurs.400
-
Potential for drug to impair mental alertness or physical coordination; avoid driving or operating machinery until effects on individual are known.238 246 f
-
Potential for severe constipation to occur.246 Advise patients on appropriate management of constipation.238 246
-
Importance of informing clinician of any breakthrough pain so that therapy may be adjusted based on individual patient requirements.238 246
-
Importance of informing patients that shell of extended-release tablet is nonabsorbable and may be passed in the stool.246
-
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as any concomitant illnesses.238 239 246 f
-
Importance of informing patients of other important precautionary information. (See Cautions.)
Additional Information
The American Society of Health-System Pharmacists, Inc. represents that the information provided in the accompanying monograph was formulated with a reasonable standard of care, and in conformity with professional standards in the field. Readers are advised that decisions regarding use of drugs are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and that the information contained in the monograph is provided for informational purposes only. The manufacturer’s labeling should be consulted for more detailed information. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information contained in the monograph is not a substitute for medical care.
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
Subject to control under the Federal Controlled Substances Act of 1970 as schedule II (C-II) drugs.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Bulk |
Powder |
|||
Oral |
Solution |
5 mg/5 mL* |
Dilaudid (C-II) |
Rhodes |
HYDROmorphone Hydrochloride Solution (C-II) |
||||
Tablets |
2 mg* |
Dilaudid (C-II) |
Rhodes |
|
HYDROmorphone Hydrochloride Tablets (C-II) |
||||
4 mg* |
Dilaudid (C-II) |
Rhodes |
||
HYDROmorphone Hydrochloride Tablets (C-II) |
||||
8 mg* |
Dilaudid (C-II; scored) |
Rhodes |
||
HYDROmorphone Hydrochloride Tablets (C-II) |
||||
Tablets, extended-release |
8 mg* |
HYDROmorphone Hydrochloride Extended-release Tablets (C-II) |
||
12 mg* |
HYDROmorphone Hydrochloride Extended-release Tablets (C-II) |
|||
16 mg* |
HYDROmorphone Hydrochloride Extended-release Tablets (C-II) |
|||
32 mg* |
HYDROmorphone Hydrochloride Extended-release Tablets (C-II) |
|||
Parenteral |
Injection |
0.2 mg/mL |
Dilaudid (C-II) |
Fresenius Kabi |
1 mg/mL* |
Dilaudid (C-II) |
Fresenius Kabi |
||
HYDROmorphone Hydrochloride Injection (C-II) |
||||
2 mg/mL* |
Dilaudid (C-II) |
Fresenius Kabi |
||
HYDROmorphone Hydrochloride Injection (C-II) |
||||
4 mg/mL* |
HYDROmorphone Hydrochloride Injection (C-II) |
|||
10 mg/mL (10, 50, or 500 mg)* |
HYDROmorphone Hydrochloride High-potency Formulation Injection (C-II) |
AHFS DI Essentials™. © Copyright 2024, Selected Revisions June 10, 2024. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.
References
238. Rhodes Pharmaceuticals. Dilaudid (hydromorphone hydrochloride) tablets and oral solution prescribing information. Coventry, RI; 2021 Mar.
239. Fresenius Kabi. Hydromorphone hydrochloride injection prescribing information. Lake Zurich, IL; 2019 Nov.
240. Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD003447. DOI: 10.1002/14651858.CD003447.
241. Principles of analgesic use in the treatment of acute pain and cancer pain. 5th ed. Glenview, IL: American Pain Society; 2004:13-41.
242. Sessler CN, Varney K. Patient-focused sedation and analgesia in the ICU. Chest. 2008; 133:552-65. http://www.ncbi.nlm.nih.gov/pubmed/18252923?dopt=AbstractPlus
243. Jacobi J, Fraser GL, Coursin DB et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med. 2002; 30:119-41. http://www.ncbi.nlm.nih.gov/pubmed/11902253?dopt=AbstractPlus
244. Murray A, Hagen NA. Hydromorphone. J Pain Symptom Manage. 2005; 29(5 Suppl):S57-66.
245. Zeltzer LK, Krane EJ, Palermo TM. Pediatric pain management. In: Kliegman RM, Stanton BF, St Geme JW III et al, eds. Nelson textbook of pediatrics. 20th ed. Philadelphia: Elsevier; 2016:430-47.
246. Ascent Pharmaceuticals. Hydromorphone hydrochloride extended-release tablets prescribing information. Central Islip, NY; 2020 Sep.
249. ASHP. Standardize 4 Safety: pediatric continuous infusion standards. Updated 2024 Mar. From ASHP website. Updates may be available at ASHP website. https://www.ashp.org/standardize4safety
250. ASHP. Standardize 4 Safety: adult continuous infusion standards. Updated 2024 Mar. From ASHP website. Updates may be available at ASHP website. https://www.ashp.org/standardize4safety
251. Fresenius Kabi. Dilaudid (hydromorphone hydrochloride) injection prescribing information. Lake Zurich, IL; 2020 Jan.
252. ASHP. Standardize 4 Safety: patient controlled analgesia (PCA) and epidural standards. Updated 2024 Mar. From ASHP website. Updates may be available at ASHP website. https://www.ashp.org/standardize4safety
253. Briggs GG, Freeman RK. Oxycodone. In: Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 10th ed. Philadelphia, PA: Wolters Kluwer; 2015: 1040-1.
254. Broussard CS, Rasmussen SA, Reefhuis J et al. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol. 2011; 204:314.e1-11.
400. US Food and Drug Administration. Drug safety communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. Silver Spring, MD; 2016 Mar 22. From FDA website. http://www.fda.gov/Drugs/DrugSafety/ucm489676.htm
401. Katz N, Mazer NA. The impact of opioids on the endocrine system. Clin J Pain. 2009; 25:170-5. http://www.ncbi.nlm.nih.gov/pubmed/19333165?dopt=AbstractPlus
402. Rajagopal A, Vassilopoulou-Sellin R, Palmer JL et al. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer. 2004; 100:851-8. http://www.ncbi.nlm.nih.gov/pubmed/14770444?dopt=AbstractPlus
403. Abs R, Verhelst J, Maeyaert J et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000; 85:2215-22. http://www.ncbi.nlm.nih.gov/pubmed/10852454?dopt=AbstractPlus
404. Fraser LA, Morrison D, Morley-Forster P et al. Oral opioids for chronic non-cancer pain: higher prevalence of hypogonadism in men than in women. Exp Clin Endocrinol Diabetes. 2009; 117:38-43. http://www.ncbi.nlm.nih.gov/pubmed/18523930?dopt=AbstractPlus
410. Nuckols TK, Anderson L, Popescu I et al. Opioid prescribing: a systematic review and critical appraisal of guidelines for chronic pain. Ann Intern Med. 2014; 160:38-47. http://www.ncbi.nlm.nih.gov/pubmed/24217469?dopt=AbstractPlus
411. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016. MMWR Recomm Rep. 2016; 65:1-49. http://www.ncbi.nlm.nih.gov/pubmed/26987082?dopt=AbstractPlus
412. Chou R, Fanciullo GJ, Fine PG et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10:113-30. http://www.ncbi.nlm.nih.gov/pubmed/19187889?dopt=AbstractPlus
413. Management of Opioid Therapy for Chronic Pain Working Group, US Department of Veterans Affairs and Department of Defense. VA/DoD clinical practice guideline for management of opioid therapy for chronic pain. 2010 May. http://www.healthquality.va.gov/guidelines/Pain/cot/COT_312_Full-er.pdf
414. Chou R, Cruciani RA, Fiellin DA et al. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain. 2014; 15:321-37. http://www.ncbi.nlm.nih.gov/pubmed/24685458?dopt=AbstractPlus
415. Manchikanti L, Abdi S, Atluri S et al. American Society of Interventional Pain Physicians (ASIPP) guidelines for responsible opioid prescribing in chronic non-cancer pain: Part 2--guidance. Pain Physician. 2012; 15(3 Suppl):S67-116.
416. Park TW, Saitz R, Ganoczy D et al. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015; 350:h2698. http://www.ncbi.nlm.nih.gov/pubmed/26063215?dopt=AbstractPlus
417. Jones CM, McAninch JK. Emergency Department Visits and Overdose Deaths From Combined Use of Opioids and Benzodiazepines. Am J Prev Med. 2015; 49:493-501. http://www.ncbi.nlm.nih.gov/pubmed/26143953?dopt=AbstractPlus
418. Dasgupta N, Funk MJ, Proescholdbell S et al. Cohort Study of the Impact of High-Dose Opioid Analgesics on Overdose Mortality. Pain Med. 2016; 17:85-98. http://www.ncbi.nlm.nih.gov/pubmed/26333030?dopt=AbstractPlus
419. Prescription Drug Monitoring Program Training and Technical Assistance Center (PDMP TTAC). Criteria for mandatory enrollment or query of PDMP. From PDMP TTAC website. Accessed 2016 Sep 14. http://www.pdmpassist.org/pdf/Mandatory_conditions.pdf
420. National Alliance for Model State Drug Laws (NAMSLD). Overview of state pain management and prescribing policies. From NAMSLD webiste. Accessed 2016 Sep 14. http://www.namsdl.org
421. Bennett A (Maine Office of Governor). Augusta, ME: 2016 Apr 19. Governor signs major opioid prescribing reform bill. Press release. http://www.maine.gov/governor/lepage/news/index.shtml
422. American Academy of Pain Medicine (AAPM). Use of opioids for the treatment of chronic pain. A statement from the American Academy of Pain Medicine. From AAPM website. 2013 Feb. http://www.painmed.org/files/use-of-opioids-for-the-treatment-of-chronic-pain.pdf
423. Franklin GM, American Academy of Neurology. Opioids for chronic noncancer pain: a position paper of the American Academy of Neurology. Neurology. 2014; 83:1277-84. http://www.ncbi.nlm.nih.gov/pubmed/25267983?dopt=AbstractPlus
424. Dunn KM, Saunders KW, Rutter CM et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med. 2010; 152:85-92. http://www.ncbi.nlm.nih.gov/pubmed/20083827?dopt=AbstractPlus
425. Gomes T, Mamdani MM, Dhalla IA et al. Opioid dose and drug-related mortality in patients with nonmalignant pain. Arch Intern Med. 2011; 171:686-91. http://www.ncbi.nlm.nih.gov/pubmed/21482846?dopt=AbstractPlus
426. Bohnert AS, Valenstein M, Bair MJ et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011; 305:1315-21. http://www.ncbi.nlm.nih.gov/pubmed/21467284?dopt=AbstractPlus
429. Paice JA, Portenoy R, Lacchetti C et al. Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016; 34:3325-45. http://www.ncbi.nlm.nih.gov/pubmed/27458286?dopt=AbstractPlus
430. Chou R, Gordon DB, de Leon-Casasola OA et al. Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016; 17:131-57. http://www.ncbi.nlm.nih.gov/pubmed/26827847?dopt=AbstractPlus
431. Washington State Agency Medical Directors' Group (AMDG). Interagency guideline on prescribing opioids for pain, 3rd ed. From Washington State AMDG website. 2015 Jun. http://www.agencymeddirectors.wa.gov/Files/2015AMDGOpioidGuideline.pdf
432. Hegmann KT, Weiss MS, Bowden K et al. ACOEM practice guidelines: opioids for treatment of acute, subacute, chronic, and postoperative pain. J Occup Environ Med. 2014; 56:e143-59.
433. Cantrill SV, Brown MD, Carlisle RJ et al. Clinical policy: critical issues in the prescribing of opioids for adult patients in the emergency department. Ann Emerg Med. 2012; 60:499-525. http://www.ncbi.nlm.nih.gov/pubmed/23010181?dopt=AbstractPlus
434. Thorson D, Biewen P, Bonte B et al, for Institute for Clinical Systems Improvement (ICSI). Acute pain assessment and opioid prescribing protocol. From ICSI website. 2014 Jan. https://www.icsi.org
435. New York City Department of Health and Mental Hygiene. New York City emergency department discharge opioid prescribing guidelines. From NYC Health website. 2013 Jan. http://www1.nyc.gov/assets/doh/downloads/pdf/basas/opioid-prescribing-guidelines.pdf
436. Chou R, Deyo R, Devine B et al. The effectiveness and risks of long-term opioid treatment of chronic pain. Evidence report/technology assessment No. 218. Rockville, MD: Agency for Healthcare Research and Quality (AHRQ); 2014 Sep. https://www.effectivehealthcare.ahrq.gov
437. Lee CKK. Drug dosages. In: Hughes HK, Kahl LK, eds. The Harriet Lane handbook. 21st ed. Philadelphia: Elsevier; 2018:915. Electronic book from Expert Consult website. Accessed 2018 Aug 3. https://expertconsult.inkling.com/read/
438. Pain Assessment and Management Initiative (PAMI). Pain management & dosing guide. Updated 2017 Oct. From PAMI website. http://pami.emergency.med.jax.ufl.edu/files/2016/01/PAMI-Dosing-Guide-October-2017.pdf
439. Friedrichsdorf SJ, Kang TI. The management of pain in children with life-limiting illnesses. Pediatr Clin N Am. 2007; 54:645-72.
440. Zernikow B, Michel E, Craig F et al. Pediatric palliative care: use of opioids for the management of pain. Pediatr Drugs. 2009; 11:129-51.
500. FDA drug safety communication . FDA updates prescribing information for all opioid pain medicines to provide additional guidance for safe use Includes updates to help reduce unnecessary prescribing; issued Apr 13 2023. From FDA website. https://www.fda.gov/media/167058/download
700. US Food and Drug Administration. Drug safety communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Silver Spring, MD; 2016 Aug 31. From FDA website. https://www.fda.gov/drugs/drugsafety/ucm518473.htm
701. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA. 2013; 309:657-9. http://www.ncbi.nlm.nih.gov/pubmed/23423407?dopt=AbstractPlus
702. Jones CM, Paulozzi LJ, Mack KA et al. Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths - United States, 2010. MMWR Morb Mortal Wkly Rep. 2014; 63:881-5. http://www.ncbi.nlm.nih.gov/pubmed/25299603?dopt=AbstractPlus
703. Hertz S. Letter to manufacturers of opioid analgesics: safety labeling change notification. Silver Spring, MD: US Food and Drug Administration. Accessed 2017 Mar 20. https://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM518611.pdf
750. Food and Drug Administration. FDA Drug Safety Communication: FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder; consider prescribing naloxone to those at increased risk of opioid overdose. 2020 Jul 23. From FDA website. Accessed 2020 Jul 28. https://www.fda.gov/media/140360/download
a. AHFS Drug Information 2021. Hydromorphone. Bethesda, MD: American Society of Health-System Pharmacists; 2021.
f. AHFS Drug Information 2006. McEvoy GK, ed. Opiate agonists general statement. Bethesda, MD: American Society of Health-System Pharmacists; 2006:2096-101.
g. Bailey PL. Clinical Pharmacology and Applications of Opioid Agonists. In: Bowdle TA, Horita A, Kharasch ED. The pharmacologic basis of anesthesiology. New York: Churchill Livingstone; 1994:105-7.
k. Srinivasan A, Budnitz D, Shehab N et al. Infant deaths associated with cough and cold medications—two states, 2005. MMWR Morb Mortal Wkly Rep. 2007; 56:1-4. http://www.ncbi.nlm.nih.gov/pubmed/17218934?dopt=AbstractPlus
l. Food and Drug Administration. Cough and cold medications in children less than two years of age. Rockville, MD; 2007 Jan 12. From FDA website. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm152111.htm
Frequently asked questions
More about hydromorphone
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (443)
- Drug images
- Latest FDA alerts (11)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: Opioids (narcotic analgesics)
- Breastfeeding
Patient resources
Professional resources
- Hydromorphone prescribing information
- Hydromorphone Extended Release (FDA)
- Hydromorphone Injection (FDA)
- Hydromorphone Oral Solution (FDA)
- Hydromorphone Suppository (FDA)
- Hydromorphone Tablets, Solution (FDA)
Other brands
Dilaudid, Exalgo, Palladone, Dilaudid-HP